Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01299766
Other study ID # 1R01AG035025
Secondary ID 1R01AG035025
Status Completed
Phase Phase 3
First received
Last updated
Start date June 21, 2011
Est. completion date December 13, 2016

Study information

Verified date November 2018
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to determine whether increasing participation in cognitive, physical, and/or social activities prevents cognitive decline in older African Americans (AAs) with Mild Cognitive Impairment (MCI). Patients with MCI are at increased risk for Alzheimer's Disease (AD); we propose that increasing participation in activities will prevent cognitive decline and may delay the onset of Alzheimer's Disease (AD). We will test this hypothesis by conducting a clinical trial in which older AAs with MCI (aged 65 years and older) will be randomized to Behavior Activation (BA) (a behavioral intervention that increases participation in daily activities) or Supportive Therapy (ST) (a person-centered psychotherapy that involves active listening and offering support focusing on participants' problems and concerns). We hypothesize that BA-treated subjects will have fewer declines in cognitive and functional abilities, fewer depressive and neuropsychiatric symptoms, and better quality of life than ST-treated subjects at 24 months.


Description:

The goal of this study is to determine whether increasing participation in activities prevents cognitive decline in older African Americans with Mild Cognitive Impairment (MCI). We will attempt to increase activities with Behavioral Activation (BA). BA is a manual-based, behavioral treatment to increase activities as a way to improve function and mood. As patients do more (through activation) and perceive the benefit (i.e., feel better), their activity levels increase. BA promotes activities that reflect an individual's preferences and goals by structuring, scheduling, and reinforcing daily activities. This increases participation in activities with strong personal value, such as social engagement or normative role function, which in turn enhances mood and motivation to remain active.

The control treatment is Supportive Therapy, which is a non-directive, supportive therapy that is based on empathy, reflection, and support.

This study is specifically targeting older African Americans (AAs). Most clinical trials for MCI have tested pharmacologic treatments and have enrolled mostly Whites; their results may not apply to AAs whose life experiences and medical and genetic characteristics may exert unique effects. Those with MCI are a high-risk population for whom interventions to prevent cognitive decline are particularly important. Because AAs comprise one of the largest minority groups in the U.S., suffer disparities in health outcomes, and are unlikely to seek pharmacologic treatments or participate in clinical drug trials, there is an urgent need to enroll older AAs in non-pharmacologic intervention studies of cognition.

We will recruit 200 AA subjects aged 65 and older who have amnestic Mild Cognitive Impairment (MCI) - Multiple Domain subtype of MCI (aMCI-MD). One of the inclusion criteria is for participants to have a Knowledgeable Informant (KI) who is willing to participate in the study (with the subject's permission as documented in the informed consent form). A KI is defined as a family member or friend who is identified by the subject as someone who has regular and frequent contact with the subject (at least twice per week) in-person or by phone. The KI will be asked to provide information regarding the subject's functioning.


Recruitment information / eligibility

Status Completed
Enrollment 221
Est. completion date December 13, 2016
Est. primary completion date December 13, 2016
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Age 65 years and older

- Having a friend/relative willing to serve as a Knowledgeable Informant (KI)

- Diagnosis of aMCI-MD

- Self-identified as African American

Exclusion Criteria:

- Psychiatric diagnosis, including dementia and major depression

- Sensory deficits that preclude neuropsychological testing

- Institutional residence

- Reduced life expectancy due to known terminal illness

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral Activation (BA)
BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
Supportive Therapy (ST)
ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.

Locations

Country Name City State
United States Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (5)

Lead Sponsor Collaborator
Thomas Jefferson University Dartmouth College, Johns Hopkins University, National Institute on Aging (NIA), University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) A decline of 6 points from baseline to 24 months on the Hopkins Verbal Learning Test-Revised (HVLT-R). Possible scores range from 0 to 12, with higher scores indicating better memory. 24 months
Secondary Change in University of California Performance-based Skills Assessment (UPSA) Score Per Year The University of California Performance-based Skills Assessment (UPSA) was used as an objective test of accuracy with writing checks, making change, using a telephone, and scheduling a physician appointment (higher scores indicate better function). Possible scores range from 0 to 100. 24 months
See also
  Status Clinical Trial Phase
Completed NCT00934531 - Donepezil and the Risk of Falls in Seniors With Cognitive Impairment N/A
Withdrawn NCT05033912 - A Study of CST-2032 in Subjects With Cognitive Impairment Phase 1
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression Phase 4
Completed NCT01212692 - Effects of Mental Stimulation in Patients With Mild Cognitive Impairment Phase 2
Recruiting NCT00544791 - The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment Phase 2
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Terminated NCT02180529 - The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment N/A
Completed NCT05108922 - A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Phase 3
Recruiting NCT05865340 - To Exam the Efficacy of Oral Health and Mediterranean Diet Interventions in Preventing Cognitive Decline Among Older Adults With Mild Cognitive Impairment N/A
Completed NCT02110043 - Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS N/A
Completed NCT01383161 - 18-Month Study of Memory Effects of Curcumin Phase 2
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04748666 - PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia N/A
Recruiting NCT03138018 - Aging Stereotypes and Prodromal Alzheimer's Disease N/A
Withdrawn NCT01891383 - Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
Recruiting NCT03448055 - Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health N/A
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Completed NCT01044758 - Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) Phase 2
Recruiting NCT05014893 - Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline N/A